Bendamustine Hydrochloride

CHEMBL1201734 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

394.7 g/mol

LogP

—

Phase

4

The hydrochloride salt of bendamustine, the commercially available formulation of this bifunctional alkylating agent. It is given intravenously and retains efficacy in some cancers resistant to other alkylating agents.

Moleküler Ağırlık

394,7000 g/mol

TPSA

58,40 Å²

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Etki Mekanizması

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21

InChI

InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H

Molecular Formula

C16H22Cl3N3O2

HBD / HBA

2 / 4

Döndürülebilir Bağlar

9

Ağır Atomlar

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrochloride salt of bendamustine, the commercially available formulation of this bifunctional alkylating agent. It is given intravenously and retains efficacy in some cancers resistant to other alkylating agents.

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Yes, Bendamustine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201734. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 77082. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Bendamustine Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H22Cl3N3O2
Eş Anlamlılar: 4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Bendamustine Hydrochloride

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget